Frontlight ResearchEarly access
WithdrawnPhase 2
FMT for Remission of Active Ulcerative Colitis in Adults
Key facts
- Who runs it
- University of British Columbia
- Where
- Canada3 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Phase
- Phase 2
- Started
- Mar 2022
- Expected to end
- Dec 2028
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- FMT oral
- FMT enema
- Placebo oral
- Placebo enema
- Record updated
- 10 May 2023
- Why it stopped
- Protocol changed substantially enough to warrant a separate submission
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Able to provide informed consent
- Willing and able to comply with all the required trial procedures
- Active ulcerative colitis as defined by Mayo score > 3 AND Mayo endoscopic sub-score > 1 (within 30 days before enrollment, or at baseline)
Who cannot take part
- Planned or actively taking another investigational product
- Abdominal surgery within the past 60 days
- Increase in medical therapy for UC within 3 months of enrollment. Continued treatment with stable dose of 5-ASA, azathioprine, 6-mercaptopurine, cyclosporine, prednisone and/or anti- TNF agents for at least 3 months of is allowed
- Requiring oral and/or intravenous systemic antibiotic therapy at the time of study enrolment
- History of anaphylaxis to any food
- Severe underlying disease such that the patient is not expected to survive for at least 30 days
- Any condition that in the opinion of the investigator that would pose harm to the participant or the research staff for the potential participant to take part in the trial
- Patients with neutropenia with absolute neutrophil count <0.5 x 109/L at - Evidence of toxic megacolon or gastrointestinal perforation on imaging
- Peripheral white blood cell count > 35.0 x 109/L at enrollment AND temperature > 38.0oC
- Active infectious diarrhea at the time of enrolment
- Severe UC requiring hospitalization at the time of enrolment
- Pregnant or lactating
- Unwilling to discontinue probiotic (yogurt is allowed)
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this study is to establish the safety and effectiveness of lyophilized (LYO) fecal microbiota transplant (FMT) for treating ulcerative colitis (UC) in adults. The protocol is being re-designed to address relevant, current research questions in the context of FMT treatment for UC. Once a final protocol is approved, this webpage will be updated.
The 3 groups in the trial
- Placebo oral & enemaPlacebo, for comparison
twice weekly x 8 weeks: 10 placebo oral capsules + placebo enema
Treatment: Placebo oral and Placebo enema
- LYO-FMT oral + placebo enemaExisting treatment, for comparison
twice weekly x 8 weeks: 10 LYO-FMT oral capsules + 1 placebo enema
Treatment: FMT oral and Placebo enema
- LYO-FMT oral + LYO-FMT enemaExisting treatment, for comparison
twice weekly x 8 weeks: 10 LYO-FMT oral capsules + 1 LYO-FMT enema
Treatment: FMT oral and FMT enema
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized Double-blind, Placebo-controlled Trial of Lyophilized Fecal Microbiota Transplantation for the Induction of Remission in Adults With Active Ulcerative Colitis
- Record updated
- 10 May 2023